Instil Bio, Inc. (TIL)
NASDAQ: TIL · Real-Time Price · USD
7.09
-0.11 (-1.53%)
At close: Jan 30, 2026, 4:00 PM EST
7.06
-0.03 (-0.42%)
After-hours: Jan 30, 2026, 4:10 PM EST
Instil Bio Employees
Instil Bio had 14 employees as of December 31, 2024. The number of employees decreased by 35 or -71.43% compared to the previous year.
Employees
14
Change (1Y)
-35
Growth (1Y)
-71.43%
Revenue / Employee
n/a
Profits / Employee
-$5,362,571
Market Cap
47.88M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 14 | -35 | -71.43% |
| Dec 31, 2023 | 49 | -143 | -74.48% |
| Dec 31, 2022 | 192 | -220 | -53.40% |
| Jun 30, 2022 | 463 | 156 | 50.81% |
| Mar 31, 2022 | 437 | 195 | 80.58% |
| Dec 31, 2021 | 412 | 262 | 174.67% |
| Sep 30, 2021 | 382 | 232 | 154.67% |
| Jun 30, 2021 | 307 | - | - |
| Mar 31, 2021 | 242 | - | - |
| Dec 31, 2020 | 150 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 70 |
| Q32 Bio | 26 |
| PDS Biotechnology | 24 |
| NeurAxis | 21 |
| iBio, Inc. | 20 |
| ABVC BioPharma | 19 |
| Lipocine | 16 |
| CervoMed | 15 |
TIL News
- 26 days ago - Instil Bio Pulls Plug On Lead Drug Development - Benzinga
- 26 days ago - Instil Bio's Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco - GlobeNewsWire
- 2 months ago - Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 5 months ago - Instil Bio Announces ImmuneOnco's Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC) - GlobeNewsWire
- 6 months ago - Instil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China - GlobeNewsWire
- 7 months ago - Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors - GlobeNewsWire
- 8 months ago - Instil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program - GlobeNewsWire